AR and prostate carcinoma: Our results show that Andrographolide can restrain proliferation and stimulate apoptosis in aggressive prostate cancer cells specifically in androgen insensitive (AI) cell (PC3) since cancer cells that undergoes androgen receptor (AR) activation can cause proliferation and block apoptosis [32].